# A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

> **NCT02110069** · PHASE2 · TERMINATED · sponsor: **Boston Children's Hospital** · enrollment: 4 (actual)

## Conditions studied

- Kaposiform Hemangioendothelioma (KHE)
- Kasabach-Merritt Syndrome
- Tufted Angioma

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02110069
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-14
- **Primary completion:** 2019-10-02
- **Final completion:** 2020-10-27
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** This study was challenged by the incidence of KHE with KMP as this continued to be extremely rare, and very sporadic. In July of 2019 grant renewal funding ended.
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02110069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02110069, "A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02110069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*